Bristol Myers Squibb (BMY) Current Deferred Revenue (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Current Deferred Revenue data on file, last reported at $168.0 million in Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $168.0 million, down 22.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $168.0 million (down 22.58% YoY), and the FY2025 annual result was $175.0 million, up 27.74% from the prior year.
• Current Deferred Revenue fell to $168.0 million in Q1 2026 per BMY's latest filing, from $175.0 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $326.0 million in Q1 2022 and troughed at $137.0 million in Q4 2024.
• A 5-year average of $250.2 million and a median of $263.0 million in 2024 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue plunged 50.0% in 2024, then gained 27.74% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $289.0 million in 2022, then fell by 5.19% to $274.0 million in 2023, then sank by 50.0% to $137.0 million in 2024, then climbed by 27.74% to $175.0 million in 2025, then declined by 4.0% to $168.0 million in 2026.
• Business Quant data shows BMY's Current Deferred Revenue at $168.0 million in Q1 2026, $175.0 million in Q4 2025, and $190.0 million in Q3 2025.